Literature DB >> 12855630

Association of increased levels of heavy-chain ferritin with increased CD4+ CD25+ regulatory T-cell levels in patients with melanoma.

Christian P Gray1, Paolo Arosio, Peter Hersey.   

Abstract

We have shown previously that melanoma cells in culture release heavy-chain ferritin (H-Ferritin) into supernatants and that this is responsible for the suppression of responses of peripheral blood lymphocytes stimulated by anti-CD3. These effects were mediated by activation of regulatory T cells to produce interleukin (IL)-10. In the present study, we examined whether a similar relation might exist between levels of H-Ferritin and activation of regulatory T cells in patients with melanoma. Ferritin levels were evaluated by ELISA and regulatory T-cell numbers were assessed by three-color flow cytometry to identify CD4(+) CD25(+) CD69(-) T cells. CD69 positive cells were excluded to avoid inclusion of normal activated CD4, CD25 expressing T cells. Measurements of H- and light-chain (L)-Ferritin by ELISA revealed that H- but not L-Ferritin was elevated in the circulation of melanoma patients. In addition, these studies revealed a marked increase in the number of CD4(+) CD25(+) CD69(-) T cells in such patients, compared with age-matched controls. The ratio of H-Ferritin:L-Ferritin correlated with the levels of regulatory T cells consistent with a causal relation between unbound H-Ferritin levels and the activation of regulatory T cells. H-Ferritin or regulatory T cells did not, however, correlate with the stage of the melanoma. These results provide evidence for the importance of H-Ferritin in the induction of regulatory T cells in patients with melanoma and provide additional insight into the suppression of immune responses in such patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12855630

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

Review 1.  Regulatory T-cell compartmentalization and trafficking.

Authors:  Shuang Wei; Ilona Kryczek; Weiping Zou
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

2.  Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells.

Authors:  K P Piper; M Karanth; A McLarnon; E Kalk; N Khan; J Murray; G Pratt; P A H Moss
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

3.  Critical stoichiometric ratio of CD4(+)  CD25(+)  FoxP3(+) regulatory T cells and CD4(+)  CD25(-) responder T cells influence immunosuppression in patients with B-cell acute lymphoblastic leukaemia.

Authors:  Kaushik Bhattacharya; Sarmila Chandra; Chitra Mandal
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

4.  Adoptive cellular therapy enhances the helper T cell response and reduces the number of regulatory T cells.

Authors:  Takeshi Ishikawa; Satoshi Kokura; Naoyuki Sakamoto; Tsuguhiro Matsumoto; Jun Funaki; Satoko Adachi; Tetsuya Okayama; Kazuhiko Uchiyama; Osamu Handa; Tomohisa Takagi; Nobuaki Yagi; Takashi Ando; Kazuko Uno; Yuji Naito; Toshikazu Yoshikawa
Journal:  Exp Ther Med       Date:  2011-05-12       Impact factor: 2.447

Review 5.  Immunotherapeutic strategies for high-risk bladder cancer.

Authors:  Padmanee Sharma; Lloyd J Old; James P Allison
Journal:  Semin Oncol       Date:  2007-04       Impact factor: 4.929

6.  Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells.

Authors:  Joel Baumgartner; Cara Wilson; Brent Palmer; Don Richter; Anirban Banerjee; Martin McCarter
Journal:  J Surg Res       Date:  2007-07       Impact factor: 2.192

7.  Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells.

Authors:  Weiyun Z Ai; Jing-Zhou Hou; Robert Zeiser; Debra Czerwinski; Robert S Negrin; Ronald Levy
Journal:  Int J Cancer       Date:  2009-01-01       Impact factor: 7.396

8.  Inherited variation in immune genes and pathways and glioblastoma risk.

Authors:  Judith A Schwartzbaum; Yuanyuan Xiao; Yanhong Liu; Spyros Tsavachidis; Mitchel S Berger; Melissa L Bondy; Jeffrey S Chang; Susan M Chang; Paul A Decker; Bo Ding; Sarah J Hepworth; Richard S Houlston; Fay J Hosking; Robert B Jenkins; Matthew L Kosel; Lucie S McCoy; Patricia A McKinney; Kenneth Muir; Joe S Patoka; Michael Prados; Terri Rice; Lindsay B Robertson; Minouk J Schoemaker; Sanjay Shete; Anthony J Swerdlow; Joe L Wiemels; John K Wiencke; Ping Yang; Margaret R Wrensch
Journal:  Carcinogenesis       Date:  2010-07-28       Impact factor: 4.944

9.  The role of regulatory T cells in cancer.

Authors:  Tai-You Ha
Journal:  Immune Netw       Date:  2009-12-31       Impact factor: 6.303

10.  Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.

Authors:  Chrystal U Louis; Karin Straathof; Catherine M Bollard; Claudia Gerken; M Helen Huls; M Victoria Gresik; Meng-Fen Wu; Heidi L Weiss; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk
Journal:  Blood       Date:  2008-10-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.